As of 2025-12-19, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (28.77) USD. This relative valuation is based on P/E multiples. With the latest stock price at 77.48 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -137.1%.
The range of the Relative Valuation is (21.18) - (30.40) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.2x - 15.9x | 13.8x |
| Forward P/E multiples | 11.1x - 18.4x | 16.3x |
| Fair Price | (21.18) - (30.40) | (28.77) |
| Upside | -127.3% - -139.2% | -137.1% |
| Date | P/E |
| 2025-12-12 | -42.55 |
| 2025-12-11 | -42.73 |
| 2025-12-10 | -42.53 |
| 2025-12-09 | -41.61 |
| 2025-12-08 | -43.01 |
| 2025-12-05 | -42.77 |
| 2025-12-04 | -42.80 |
| 2025-12-03 | -42.83 |
| 2025-12-02 | -41.55 |
| 2025-12-01 | -41.83 |
| 2025-11-28 | -41.82 |
| 2025-11-26 | -42.11 |
| 2025-11-25 | -41.26 |
| 2025-11-24 | -42.95 |
| 2025-11-21 | -41.67 |
| 2025-11-20 | -40.26 |
| 2025-11-19 | -40.33 |
| 2025-11-18 | -40.26 |
| 2025-11-17 | -38.79 |
| 2025-11-14 | -38.14 |
| 2025-11-13 | -37.94 |
| 2025-11-12 | -39.13 |
| 2025-11-11 | -39.56 |
| 2025-11-10 | -38.07 |
| 2025-11-07 | -35.70 |
| 2025-11-06 | -35.61 |
| 2025-11-05 | -35.67 |
| 2025-11-04 | -37.40 |
| 2025-11-03 | -36.50 |
| 2025-10-31 | -35.99 |
| 2025-10-30 | -36.07 |
| 2025-10-29 | -35.32 |
| 2025-10-28 | -35.34 |
| 2025-10-27 | -35.65 |
| 2025-10-24 | -34.55 |
| 2025-10-23 | -35.74 |
| 2025-10-22 | -35.93 |
| 2025-10-21 | -37.04 |
| 2025-10-20 | -37.24 |
| 2025-10-17 | -38.15 |
| 2025-10-16 | -39.21 |
| 2025-10-15 | -39.20 |
| 2025-10-14 | -36.52 |
| 2025-10-13 | -36.79 |
| 2025-10-10 | -36.69 |
| 2025-10-09 | -36.81 |
| 2025-10-08 | -36.48 |
| 2025-10-07 | -35.79 |
| 2025-10-06 | -35.42 |
| 2025-10-03 | -34.09 |